<DOC>
	<DOC>NCT00983996</DOC>
	<brief_summary>The objective of this study is to investigate the bioequivalence of Mylan's alendronate sodium 10 mg tablets to Merck's Fosamax 10 mg tablets following a single, oral 40 mg (4 x 10 mg) dose administration under fasting conditions.</brief_summary>
	<brief_title>Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)</brief_title>
	<detailed_description />
	<mesh_term>Alendronate</mesh_term>
	<criteria>healthy, adult subjects, 18 years and older able to swallow medication institutionalized subjects history of any significant disease use of any prescription or OTC medications within 14 days of start of study received any investigational products within 30 days prior to start of study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>